

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		<i>Complete if Known</i>	
		Application Number	10/048,072
		Filing Date	January 25, 2002
		First Named Inventor	Franchini, Genoveffa
		Group Art Unit	1648
		Examiner Name	Parkin, Jeffrey
Sheet 1 of 2		Attorney Docket No: 1662.018US1	

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
--------------------	---------------------	------------------	---	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-0108702A3	02/08/2001	Franchini, Genoveffa , et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 04-28-05", 3 pgs	
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Office Action mailed 09-03-07", 5 pgs	
		"International Application Serial No. 00953728.3 (Atty Ref 1662.018EP1), Response filed 10-11-05 to Office Action mailed 04-28-05", 9 pgs	
		"International Application Serial No. PCT/US00/20641 (Atty Ref 1662.018EP1), International Preliminary Examination Report mailed 11-28-01", 5 pgs	
		AUTRAN, B. , et al., "Therapeutic vaccines for chronic infections", <u>Science</u> , 305(5681), (July 9, 2004),205-8	
		DORRELL, L. , et al., "Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine", <u>J Virol.</u> , 80(10), (May, 2006),4705-16	
		JOHN, M. , et al., "Control of HIV Replication by Cytotoxic T-Lymphocyte responses", <u>Journal of HIV Therapy</u> , 4(4), (1999),91-97	
		KINLOCH-DE LOES, S. , et al., "pact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.", <u>J Infect Dis.</u> , 192(4), (Aug. 15, 2005),607-17	
		MWAU, M. , et al., "A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans", <u>J Gen Virol.</u> , 85(Pt 4), (Apr., 2004),911-9	
		PAOLETTI, E. , et al., "Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC", <u>Dev Biol Stand.</u> , 84, (1995),159-163	
		PIALOUX, G. , et al., "A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA", <u>AIDS Res Hum Retroviruses.</u> , 11(3), (1995),373-381	
		ROSENWIRTH, B. , et al., "An anti-HIV strategy combining chemotherapy and therapeutic vaccination", <u>J Med Primatol.</u> , 28(4-5), (1999),195-205	

/Jeffrey Parkin/

EXAMINER

DATE CONSIDERED

03/31/2008

<p>Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i></p>		<i>Complete if Known</i>	
		Application Number	10/048,072
		Filing Date	January 25, 2002
		First Named Inventor	Franchini, Genoveffa
		Group Art Unit	1648
		Examiner Name	Parkin, Jeffrey
Sheet 2 of 2		Attorney Docket No: 1662.018US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TUBIANA, R. , et al., "Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094).", <u>Vaccine</u> , 23(34), (July 29, 2005),4292-301	

EXAMINER

/Jeffrey Parkin/

DATE CONSIDERED

03/31/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique identifier designation number (optional) - Applicant is to place a check mark before English language. Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./